>BEC Abstracts from www.rationaltherapeutics.com. Dr. Nagourneys >page >#1070 BEC, A Mixture Of Solasodine Glycosides Reveals Cytotoxic >Activity In Human Tumor Primary Culture Specimens: Pre-Clinical And >Early Clinical Observations: YZ Su, DG Spall, MA Traill, C Kollin, C >Chow, B. Sommers, S. Harper, D Horlick, SS Evans and RA Nagourney. >Rational Theraputics, Inc. Long Beach, CA 90806 and OncoCare Cancer >and Prostcare Clinic, Melbourne Australia. > >BEC, a mixture of glycoalkaloids extracted from Solanum Sodomaeum >has shown activity in human tumor cell lines (Cham, BE. Canc. Lett. >55:1990). To characterize the cytotoxicity of BEC for human tumors >we applied an ex vivo cell death assay (EVA) in 23 fresh human tumor >specimens. These included 8 Gynecologic (Gyn); 6 GI; 2 NSCLC; 2 >Breast (Bre) & 2 Sarcomas (Sar). In addition BEC activity was >compared with other cytotoxic agents, including Cisplatin (CDDP); >Doxorubicin (Dox), Paclitaxel (P); Nitrogen Mustard (NM); >Vinorelbine (V); Topotecan (T); Etoposide (E); Gemcitabine (Gem) and >Arsenic Trioxide (ARS). IC50 results for all 23 studies revealed a >Median of 8.8 ug/ml and a Mean of 8.6 +/- 1 ug/ml (SEM). Mean IC50 >(ug/ml) by tumor type revealed Sar = 3.1; GI = 6.3; Bre = 7.8; Gyn = >9.6; NSCLC = 14.5. A comparison of Mean IC50 values for BEC against >other drugs revealed correlation coefficients (R values) for NM of >0.76 (p<0.001) and for Gem of 0.45 (p<0.05) but no correlation with >T, E, CDDP, P, V or ARS. Under Australian Special Access >Experimental Drug Use Guidelines, 8 patients have received IV >infusions of BEC at doses of 50 mg/m2 to 125 mg/m2, daily X 5 for 2 >weeks/month, for a total of 10 cycles to date. Toxicities have >included rigors, fever, chemical phlebitis and reversible elevations >of the transaminases. No hematologic, renal, cardiac or neurological >toxicities were observed. Dose escalations and assessments of >response continue. Conclusions: BEC reveals cytotoxic activity in >human tumors. The ex vivo activity profile of BEC correlates with NM >& Gem. Preliminary results indicate that BEC can be administered IV >at up to 125 mg/m2. Cell death assays provide drug and disease >specific information that can streamline novel agent development. >Supported by The Vanguard Cancer Foundation and the Tina Robinson >Cancer Research Fund.
SBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held